BX Maintained by Oppenheimer -- Price Target Raised to $171

Blackstone Inc. is selling up to 11.1 million units (25.03%) of its stake in Knowledge Realty Trust, valued at $1.25 billion. The sale, priced at a 4.7% discount, will reduce Blackstone's ownership to 21.5% if fully exercised, making Sattva Group the largest shareholder with 32%.

Oppenheimer Holdings stock rose 2.7% in pre-market trading to $123.25, surpassing its 52-week high, as the company distributed a $0.20 per share dividend. This follows strong Q2 2026 earnings, with revenue up 21.9% YoY to $454.9M and adjusted EPS at $4.27. Client assets under management reached a record $59.4B. The stock's technical breakout and positive fundamentals drove the gain, independent of broader market trends.

Oppenheimer maintained an 'Outperform' rating for Revolution Medicines (RVMD) and raised its price target from $230 to $260. The biotech company has a $46.8B market cap but faces profitability and growth concerns, with a GF Score of 25/100. Insiders have sold $54.5M in shares over the past three months.

NVIDIA (NVDA) partnered with six financial firms, including Blackstone (BX), to launch 'compute financing platforms' aiming to raise over $500 billion for AI infrastructure. NVIDIA may backstop 25% of deals. Blackstone's president sees AI compute as a financeable asset class. NVIDIA shares fell after the announcement, erasing $70 billion in market value, amid skepticism about AI spending.

The European Commission approved Blackstone's plan to invest up to EUR 2 billion in Eurowind Energy, a Danish renewable energy developer. Blackstone will gain a minority stake and support the company's growth.

Carlyle (CG) reported Q2 revenues of $1.11B, up 13% YoY, exceeding estimates by 20.7%. The stock is down 3.8% since reporting. Five asset management firms beat revenue estimates by 8.4% on average, with shares up 8.2% since earnings.